— Know what they know.
Not Investment Advice

MLYS NASDAQ

Mineralys Therapeutics, Inc.
1W: +10.8% 1M: +4.5% 3M: +8.4% YTD: -15.3% 1Y: +87.8% 3Y: +93.2%
$29.85
-0.38 (-1.26%)
 
Weekly Expected Move ±8.2%
$23 $25 $27 $30 $32
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 56 · $2.0B mcap · 46M float · 2.71% daily turnover · Short 58% of daily vol

Cash Flow Trends

Operating Cash Flow
-$142M +14.4% ▲
Capital Expenditures
$15K +84.4% ▲
Free Cash Flow
-$142M +14.4% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$59M -9.2% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$19M-$30M-$72M-$178M-$155M
Depreciation & Amort.$0$0$0$43K$59K
Stock-Based Comp.$80K$455K$5M$11M$19M
Change in Working Capital$4M$772K-$7M$10M$3M
Other Non-Cash Items$684K-$649K-$7M-$9M-$10M
Operating Cash Flow-$15M-$29M-$81M-$166M-$142M
— Investing Activities —
Capital Expenditures$0$0$0-$96K-$15K
Acquisitions (Net)$0$0$0$0$0
Investment Purchases$0-$72M-$348M-$373M-$815M
Investment Sales$0$50M$188M$488M$425M
Other Investing$0$0$0$0$0
Investing Cash Flow$0-$22M-$160M$115M-$390M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0-$2M$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$0$0$258K$83K$0
Financing Cash Flow$24M$128M$203M$116M$591M
Net Change in Cash$9M$77M-$38M$65M$59M
Cash End of Period$11M$88M$49M$114M$173M
Free Cash Flow-$15M-$29M-$81M-$166M-$142M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms